Cochrane · systematic review · CD013377
Therapeutic vaccines for advanced non‐small cell lung cancer
Cortés-Jofré, M, Rueda-Etxebarria, M, Orillard, E, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
Lung CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
9
No studies
3
Included studies
NR
No studies 3 · 25%Ungraded 0 · 0%Very low 2 · 16.7%Low 7 · 58.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
TG4010 added to chemotherapy compared to chemotherapy alone in first‐line treatment
Population: adults with advanced non‐small cell lung cancer (NSCLC)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival TG4010 added to chemotherapy vs chemotherapy alone | HR 0.83 [0.65, 1.05] | 2 studies · 370 participants | Low Downgraded: imprecision |
Progression‐free survival TG4010 added to chemotherapy vs chemotherapy alone | HR 0.74 [0.55, 0.99] | 1 study · 222 participants | Low Downgraded: imprecision |
Participants with at least one serious adverse event TG4010 added to chemotherapy vs chemotherapy alone | RR 0.7 [0.23, 2.19] | 2 studies · 362 participants | Very low Downgraded: imprecision, inconsistency |
Survival rates at 3 years TG4010 added to chemotherapy vs chemotherapy alone | RR 1 [0.3, 3.31] | 1 study · 148 participants | Low Downgraded: imprecision |
Survival rates at 5 years TG4010 added to chemotherapy vs chemotherapy alone | no estimate extracted | NR | No studies |
Health‐related quality of life TG4010 added to chemotherapy vs chemotherapy alone | no estimate extracted | NR | No studies |
Epidermal growth factor versus best supportive care for switch maintenance after first‐line treatment
Population: adults with advanced non‐small cell lung cancer (NSCLC)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Epidermal growth factor vs best supportive care | HR 0.82 [0.66, 1.02] | 1 study · 378 participants | Low Downgraded: imprecision |
Progression‐free survival Epidermal growth factor vs best supportive care | no estimate extracted | NR | No studies |
Participants with at least one serious adverse event Epidermal growth factor vs best supportive care | RR 1.32 [0.88, 1.98] | 2 studies · 458 participants | Low Downgraded: imprecision |
Survival rates at 3 years Epidermal growth factor vs best supportive care | RR 1.45 [0.82, 2.54] | 2 studies · 458 participants | Low Downgraded: imprecision |
Survival rates at 5 years Epidermal growth factor vs best supportive care | RR 3.4 [1.02, 11.27] | 1 study · 378 participants | Low Downgraded: imprecision |
Health‐related quality of life Epidermal growth factor vs best supportive care | MD 7.9 | 1 study · 86 participants | Very low Downgraded: risk of bias, imprecision |